IL13 and lymphedema: The inhibition of Th2 differentiation with IL-4- or IL-13-neutralizing antibodies prevents the initiation and progression of lymphedema by inhibiting tissue fibrosis and improving lymphatic function in another mouse tail lymphedema model [27].